This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aloj, L. Articles by Neumann, R. D. Search for Related Content PubMed PubMed Citation Articles by Aloj, L. Articles by Neumann, R. D.

Glut-1 and Hexokinase Expression

Relationship with 2-Fluoro-2-deoxy-D-glucose Uptake in A431 and T47D Cells in Culture

Nuclear Medicine [L. A., R. D. N.] and Positron Emission Tomography [C. C., E. J., W. C. E.] Departments, Clinical Center, NIH, Bethesda, Maryland, 20892-1180

Uptake of 2-[¹⁸F]-2-deoxy-D-glucose (FDG) has been used as a marker of increased glucose metabolism to visualize, stage, and monitor progression of human cancers with positron emission tomography. Many human tumors have been shown to overexpress the Glut-1 glucose transport protein. The aim of this study is to define whether a quantitative relationship exists between the amount of Glut-1 expressed by cells and their ability to accumulate FDG. We characterized the expression of the known facilitative and sodium-dependent glucose transporter isoforms in six different cancer cell lines used in our laboratory (A431, MDA-MB-231, T47D, CaCo II, MCF7, and HepG2). A431 and T47D cells express, respectively, the highest and lowest amount of Glut-1 mRNA by Northern blot of all of the cells analyzed, and no other glucose transporter isoforms were detectable by this method in both cell lines. Both total and plasma membrane-associated Glut-1 protein levels were higher in A431 than in T47D cells, consistent with the higher Glut-1 mRNA levels. However, T47D cells accumulate FDG more rapidly than do A431 cells. 3-O-Methyl-glucose transport is higher in A431 cells. Although hexokinase I and II mRNA levels are higher in A431 cells than in T47D cells, the ability of mitochondrial preparations to phosphorylate FDG is higher in T47D cells. Our data indicate that in these cultured cells, FDG uptake correlates better with FDG phosphorylating activity of mitochondrial preparations rather than the level of expression of the Glut-1 or hexokinase I and II genes.

This article has been cited by other articles:

				K. J. Ahn, H. S. Hwang, J. H. Park, S. H. Bang, W. J. Kang, M. Yun, and J. D. Lee Evaluation of the Role of Hexokinase Type II in Cellular Proliferation and Apoptosis Using Human Hepatocellular Carcinoma Cell Lines J. Nucl. Med., September 1, 2009; 50(9): 1525 - 1532. [Abstract] [Full Text] [PDF]

				L. H. Wei, H. Su, I. J. Hildebrandt, M. E. Phelps, J. Czernin, and W. A. Weber Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma Clin. Cancer Res., June 1, 2008; 14(11): 3416 - 3426. [Abstract] [Full Text] [PDF]

				T. A.D. Smith and M. G. Blaylock Treatment of Breast Tumor Cells In Vitro with the Mitochondrial Membrane Potential Dissipater Valinomycin Increases 18F-FDG Incorporation J. Nucl. Med., August 1, 2007; 48(8): 1308 - 1312. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]

				H. Su, C. Bodenstein, R. A. Dumont, Y. Seimbille, S. Dubinett, M. E. Phelps, H. Herschman, J. Czernin, and W. Weber Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors. Clin. Cancer Res., October 1, 2006; 12(19): 5659 - 5667. [Abstract] [Full Text] [PDF]

				W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]

				J. M. Engles, S. A. Quarless, E. Mambo, T. Ishimori, S. Y. Cho, and R. L. Wahl Stunning and Its Effect on 3H-FDG Uptake and Key Gene Expression in Breast Cancer Cells Undergoing Chemotherapy J. Nucl. Med., April 1, 2006; 47(4): 603 - 608. [Abstract] [Full Text] [PDF]

				T. Akhurst, T. J. Kates, M. Mazumdar, H. Yeung, E. R. Riedel, B. M. Burt, L. Blumgart, W. Jarnagin, S. M. Larson, and Y. Fong Recent Chemotherapy Reduces the Sensitivity of [18F]Fluorodeoxyglucose Positron Emission Tomography in the Detection of Colorectal Metastases J. Clin. Oncol., December 1, 2005; 23(34): 8713 - 8716. [Abstract] [Full Text] [PDF]

				J. D. Lee, W. I. Yang, Y. N. Park, K. S. Kim, J. S. Choi, M. Yun, D. Ko, T.-S. Kim, A. E.H. Cho, H. M. Kim, et al. Different Glucose Uptake and Glycolytic Mechanisms Between Hepatocellular Carcinoma and Intrahepatic Mass-Forming Cholangiocarcinoma with Increased 18F-FDG Uptake J. Nucl. Med., October 1, 2005; 46(10): 1753 - 1759. [Abstract] [Full Text] [PDF]

				S. Zhao, Y. Kuge, T. Mochizuki, T. Takahashi, K. Nakada, M. Sato, T. Takei, and N. Tamaki Biologic Correlates of Intratumoral Heterogeneity in 18F-FDG Distribution with Regional Expression of Glucose Transporters and Hexokinase-II in Experimental Tumor J. Nucl. Med., April 1, 2005; 46(4): 675 - 682. [Abstract] [Full Text] [PDF]

				A. K. Buck and S. N. Reske Cellular Origin and Molecular Mechanisms of 18F-FDG Uptake: Is There a Contribution of the Endothelium? J. Nucl. Med., March 1, 2004; 45(3): 461 - 463. [Full Text]

				R. A. Medina, A. M. Meneses, J. C. Vera, C. Guzman, F. Nualart, A. Astuya, M. de los Angeles Garcia, S. Kato, A. Carvajal, M. Pinto, et al. Estrogen and Progesterone Up-Regulate Glucose Transporter Expression in ZR-75-1 Human Breast Cancer Cells Endocrinology, October 1, 2003; 144(10): 4527 - 4535. [Abstract] [Full Text] [PDF]

				R. L. Aft, J. S. Lewis, F. Zhang, J. Kim, and M. J. Welch Enhancing Targeted Radiotherapy by Copper(II)diacetyl- bis(N4-methylthiosemicarbazone) Using 2-Deoxy-D-Glucose Cancer Res., September 1, 2003; 63(17): 5496 - 5504. [Abstract] [Full Text] [PDF]

				T. Atsumi, J. Chesney, C. Metz, L. Leng, S. Donnelly, Z. Makita, R. Mitchell, and R. Bucala High Expression of Inducible 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (iPFK-2; PFKFB3) in Human Cancers Cancer Res., October 15, 2002; 62(20): 5881 - 5887. [Abstract] [Full Text] [PDF]

				T. Higashi, T. Saga, Y. Nakamoto, T. Ishimori, M. H. Mamede, M. Wada, R. Doi, R. Hosotani, M. Imamura, and J. Konishi Relationship Between Retention Index in Dual-Phase 18F-FDG PET, and Hexokinase-II and Glucose Transporter-1 Expression in Pancreatic Cancer J. Nucl. Med., February 1, 2002; 43(2): 173 - 180. [Abstract] [Full Text] [PDF]

				P. Burgman, J. A. O'Donoghue, J. L. Humm, and C. C. Ling Hypoxia-Induced Increase in FDG Uptake in MCF7 Cells J. Nucl. Med., January 1, 2001; 42(1): 170 - 175. [Abstract] [Full Text] [PDF]

				T. A.D. Smith, N. R. Maisey, J. C. Titley, L. E. Jackson, M. O. Leach, and S. M. Ronen Treatment of SW620 Cells with Tomudex and Oxaliplatin Induces Changes in 2-Deoxy-D-Glucose Incorporation Associated with Modifications in Glucose Transport J. Nucl. Med., October 1, 2000; 41(10): 1753 - 1759. [Abstract] [Full Text] [PDF]

				D. Rivenzon-Segal, E. Rushkin, S. Polak-Charcon, and H. Degani Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells Am J Physiol Endocrinol Metab, September 1, 2000; 279(3): E508 - E519. [Abstract] [Full Text] [PDF]